Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Virpax Pharmaceuticals, Inc. VRPX
$0.85
-$0.01 (-0.86%)
На 18:04, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
8785725.00000000
-
week52high
1.83
-
week52low
0.61
-
Revenue
0
-
P/E TTM
0
-
Beta
2.03818100
-
EPS
-1.76000000
-
Last Dividend
0.00000000
-
Next Earnings Date
18 мая 2021 г. в 12:30
Описание компании
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical nonsteroidal anti-inflammatory drug treatment for chronic osteoarthritis of the knee; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise PES200, which enables the delivery of a metabolically labile peptide drug into the brain; AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and VRP324, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Maxim Group | Buy | 09 июн 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Chipman Christopher Michael | A | 112000 | 112000 | 25 янв 2023 г. |
| Mack Anthony P. | A | 125000 | 125000 | 25 янв 2023 г. |
| Gudin Jeffrey | A | 50000 | 50000 | 25 янв 2023 г. |
| Singh Vanila | A | 15000 | 15000 | 01 янв 2023 г. |
| Dubin Michael F | A | 20000 | 20000 | 01 янв 2023 г. |
| Sendrow Jerrold | A | 35000 | 35000 | 01 янв 2023 г. |
| Floyd Eric | A | 45000 | 45000 | 01 янв 2023 г. |
| Jambulingam Thani | A | 40000 | 40000 | 01 янв 2023 г. |
| Sendrow Jerrold | A | 9006 | 4500 | 24 мая 2022 г. |
| Mack Anthony P. | A | 252562 | 75750 | 18 мая 2022 г. |
Новостная лента
Virpax Pharma Expands AnQlar Worldwide Licensing Pact In COVID-19
Benzinga
15 мар 2022 г. в 13:56
Virpax Pharmaceuticals Inc (NASDAQ: VRPX) expanded its exclusive license agreement for AnQlar with Nanomerics Ltd, providing Virpax with the worldwide rights for development and commercialization. Virpax has completed in-vitro, ex-vivo (human mucosal cells), and in-vivo (rats).
Virpax Pharmaceuticals Stock (VRPX): Why The Price Increased Today
Pulse2
08 дек 2021 г. в 15:09
The stock price of Virpax Pharmaceuticals Inc (NASDAQ: VRPX) increased by over 38% during intraday trading today. This is why it happened.
4 Reddit Penny Stocks To Buy For Under $5 As Trump Stocks Jump
PennyStocks
08 дек 2021 г. в 12:22
4 Reddit penny stocks to watch right now. The post 4 Reddit Penny Stocks To Buy For Under $5 As Trump Stocks Jump appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Best Penny Stocks To Buy Today? Retail Traders Are Watching These Now
PennyStocks
20 сент 2021 г. в 10:32
Penny stocks bouncing back after the stock market sell-off The post Best Penny Stocks To Buy Today? Retail Traders Are Watching These Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Virpax® Pharmaceuticals Announces Closing of $40 Million Public Offering of Common Stock
Business Wire
16 сент 2021 г. в 13:00
BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax® Pharmaceuticals Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX), a company specializing in developing pharmaceutical products for pain management, today announced the closing of an underwritten public offering of 6,670,000 shares of its common stock at a public offering price of $6.00 per share, for gross proceeds of $40,020,000, before deducting underwriting discounts and offering expenses. In addition, Virpax has granted the underwriters a 45-day option to